DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Summary for Patent: 8,105,788
|Title:||Mucopolysaccharidosis (MPS) diagnostic methods, systems, kits and assays associated therewith|
|Abstract:||Methods, systems, kits and assays for diagnosing, monitoring or screening for mucopolysaccharidosis (MPS) and methods and systems for assaying test compounds for therapeutic activity are described, whereby MPS marker protein levels are assayed as an indication of MPS.|
|Inventor(s):||Clarke; Lorne A. (West Vancouver, CA), Randall; Derrick Raymond (Burnaby, CA), Sinclair; Graham (Victoria, CA)|
|Assignee:||The University of British Columbia (Vancouver, CA)|
|Patent Claims:||1. A method of identifying a compound that promotes glycosaminoglycan (GAG) degradation, the method comprising: (1) (a) providing a cell having reduced enzyme activity
resulting in accumulation of undegraded or partially degraded GAGs, wherein the enzyme is involved in degrading GAGs and contacting the cell with one or more test compounds; or (b) providing a mucopolysaccharidoses (MPS) experimental animal having
reduced enzyme activity resulting in an accumulation of undegraded or partially degraded GAGs and administering to the experimental animal one or more test compounds; and (2) determining whether there is a relative increase or decrease of MPS marker as
a result of the administration of one or more test compounds, whereby any compound that promotes GAG degradation is identified.
2. The method of claim 1, wherein MPS marker is selected from one or more of the following markers: Fibrinogen, .gamma.-polypeptide; Fibrinogen, .alpha.-polypeptide; .alpha.-1-antitrypsin 1-5; Inter-.alpha. trypsin inhibitor, heavy chain 1; Apolipoprotein B; Pzp protein; Gelsolin; Kininogen precursor; Histidine-rich glycoprotein; Alpha-1 proteinase inhibitor 2; Apolipoprotein C-III; Factor XIII beta; Paraoxonase 1; Heparin cofactor II thrombin complex (HCII-T); and Heparin cofactor II (HCII).
3. The method of claim 2, wherein the one or more test compounds increases HCII levels, or wherein the one or more test compounds decreases HCII-T levels.
4. The method of claim 1, further comprising administering any identified compound to a test subject.
5. The method of claim 1, further comprising incorporating any identified compound into a medicament.
6. A method for identifying an individual having mucopolysaccharidoses (MPS), or determining whether an individual is at risk for MPS, the method comprising: testing at least one biological sample from the individual in an MPS marker detection assay, operable for determining relative MPS marker levels, wherein an MPS marker level different from the MPS marker level in a normal subject is indicative of MPS status.
7. The method of claim 6, wherein MPS marker is selected from one or more of the following: Fibrinogen, .gamma.-polypeptide; Fibrinogen, .alpha.-polypeptide; .alpha.-1-antitrypsin 1-5; Inter-.alpha. trypsin inhibitor, heavy chain 1; Apolipoprotein B; Pzp protein; Gelsolin; Kininogen precursor; Histidine-rich glycoprotein; Alpha-1 proteinase inhibitor 2; Apolipoprotein C-III; Factor XIII beta; Paraoxonase 1; Heparin cofactor II thrombin complex (HCII-T), and Heparin cofactor II (HCII).
8. The method of claim 6, wherein the MPS marker is HCII, and a decreased HCII level is indicative of MPS, or wherein the MPS marker is HCII-T, and an increased HCII-T level is indicative of MPS.
9. The method of claim 6, further comprising administering a treatment to the subject identified as having MPS or at risk for MPS.
10. The method of claim 9, wherein the treatment comprises Aldurazyme.RTM. (laronidase) administration.
11. The method of claim 9, wherein the treatment comprises a bone marrow transplant.
12. The method of claim 9, wherein the biological sample is collected one or more times prior to, during or after treatment.
Summary for Patent: Start Trial
|PCT Filed||December 08, 2006||PCT Application Number:||PCT/CA2006/002011|
|PCT Publication Date:||June 14, 2007||PCT Publication Number:||WO2007/065273|
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Biomarin||ALDURAZYME||laronidase||VIAL||125058||001||2003-04-30||Start Trial||The University of British Columbia (Vancouver, CA)||2039-03-29||RX||Orphan||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.